Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
The investigators explored the safety and activity of weekly irinotecan liposomes in patients with relapsed and metastatic Ewing Sarcoma.
Trial Details
- NCT ID
- NCT06340204
- Phase
- PHASE1
- Sponsor
- Peking University People's Hospital
- Status
- RECRUITING
- Cancer Type
- Osteosarcoma Sarcoma
- Interventions
- Irinotecan Hydrochloride Liposome Injection
- Locations (sample)
- Jina, Shandong, China
- Beijin, China|35.93305,111.40836
- Beijing, China|39.9075,116.39723
Key Eligibility Criteria
- Histologically confirmed Ewing sarcoma
- Evidence of Ewing sarcoma translocation by fluorescence in situ hybridization (FISH) or real-time polymerase chain reaction (RT-PCT).
- Recurrent or refractory tumors with no known curative treatment options according to the judgment of the investigator.
- Prior treatment consisted of standard Ewing Sarcoma chemotherapy agents including doxorubicin, vincristine, cyclophosphamide, ifosfamide and etopos…
For full eligibility, visit ClinicalTrials.gov.